CTA101

BIOLOGICAL3 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, Kai Lin Xu; Jun Nian Zheng, He Huang

Conditions

Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaNon-hodgkin Lymphoma

Early Phase 1

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

RecruitingNCT04227015

He HuangAcute Lymphoblastic Leukemia, Non-hodgkin Lymphoma

Start: 2020-01-08End: 2027-05-31Target: 72Updated: 2020-12-28

Phase 1

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

The First Affiliated Hospital with Nanjing Medical UniversityDiffuse Large B-cell Lymphoma

Start: 2019-12-01End: 2022-12-31Target: 9Updated: 2019-10-31

CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

Kai Lin Xu; Jun Nian ZhengAcute Lymphoblastic Leukemia

Start: 2019-12-10End: 2022-06-30Target: 15Updated: 2020-01-14

Related Papers

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood2020-11-0514 citations